DOP2011000173A - Compuestos organico - Google Patents
Compuestos organicoInfo
- Publication number
- DOP2011000173A DOP2011000173A DO2011000173A DO2011000173A DOP2011000173A DO P2011000173 A DOP2011000173 A DO P2011000173A DO 2011000173 A DO2011000173 A DO 2011000173A DO 2011000173 A DO2011000173 A DO 2011000173A DO P2011000173 A DOP2011000173 A DO P2011000173A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- organic compounds
- compounds
- pirazolo
- ona
- uncle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE DESCRIBEN COMPUESTOS 3-(TIO, SULFINIL O SULFONIL) -7,8-DIHIDRO-(1H ó 2H) -IMIDAZO{1,2-A}PIRAZOLO {4,3-E} PIRIMIDIN-4(5H)-ONA OPCIONALMENTE SUBSTITUIDA O UNA 3-(TIO,SULFINIL O SULFONIL)-7,8,9-TRIHYDRO-(1H ó 2H)-PIRIMIDO {1,2-A}PIRAZOLO{4,3-E}PIRIMIDIN-4(5H)-ONA SUBSTITUIDA O COMPUESTOS DE LA FORMULA (I), PROCEDIMIENTOS PARA SU PRODUCCION, SU USO COMO FARMACEUTICOS Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12044208P | 2008-12-06 | 2008-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2011000173A true DOP2011000173A (es) | 2011-10-31 |
Family
ID=42233533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2011000173A DOP2011000173A (es) | 2008-12-06 | 2011-06-06 | Compuestos organico |
Country Status (23)
Country | Link |
---|---|
US (4) | US8536159B2 (es) |
EP (1) | EP2367429B1 (es) |
JP (1) | JP5778582B2 (es) |
KR (1) | KR20110095881A (es) |
CN (1) | CN102231953A (es) |
AU (1) | AU2009322901A1 (es) |
BR (1) | BRPI0922348A2 (es) |
CA (1) | CA2740391A1 (es) |
CL (1) | CL2011001263A1 (es) |
CO (1) | CO6390083A2 (es) |
CR (1) | CR20110312A (es) |
DO (1) | DOP2011000173A (es) |
EA (1) | EA201170770A1 (es) |
EC (1) | ECSP11011184A (es) |
ES (1) | ES2638912T3 (es) |
IL (1) | IL213314A0 (es) |
MA (1) | MA32938B1 (es) |
MX (1) | MX2011005933A (es) |
PE (1) | PE20110922A1 (es) |
SG (1) | SG171775A1 (es) |
TN (1) | TN2011000246A1 (es) |
WO (1) | WO2010065149A1 (es) |
ZA (1) | ZA201103631B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
CA2651519A1 (en) | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
ES2411604T3 (es) * | 2006-11-13 | 2013-07-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
MX2010006208A (es) * | 2007-12-06 | 2010-12-21 | Intra Cellular Therapies Inc | Compuestos organicos. |
AU2008335811B2 (en) | 2007-12-06 | 2012-05-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
US8536159B2 (en) * | 2008-12-06 | 2013-09-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
BRPI0922808A2 (pt) | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
BRPI0922131A2 (pt) * | 2008-12-06 | 2015-08-18 | Intracellular Therapies Inc | Compostos orgânicos |
KR20110098732A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
JP5710492B2 (ja) | 2008-12-06 | 2015-04-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
JP2012518685A (ja) * | 2009-02-25 | 2012-08-16 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 眼障害のためのpde1阻害剤 |
JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
EP2485771A4 (en) * | 2009-10-08 | 2014-11-12 | Intra Cellular Therapies Inc | PLATORS TARGETING PHOSPHODESTERASE 1 AND ASSOCIATED METHODS |
WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
WO2012171016A1 (en) * | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
JP6240180B2 (ja) | 2012-06-18 | 2017-11-29 | ダート・ニューロサイエンス・(ケイマン)・リミテッド | 置換チオフェン−およびフラン−縮合アゾロピリミジン−5−(6h)−オン化合物 |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP2956141A4 (en) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | NEW USES |
PL2970279T3 (pl) | 2013-03-15 | 2021-05-31 | Intra-Cellular Therapies, Inc. | Związki organiczne |
US9545406B2 (en) | 2013-03-15 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Method of treating a CNS injury with a PDE1 inhibitor |
MX2015017972A (es) | 2013-06-21 | 2016-10-28 | Intra-Cellular Therapies Inc | Cristales de base libre. |
EP3091983B1 (en) | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
EP3157926B1 (en) | 2014-06-20 | 2019-05-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
BR112016029338A2 (pt) | 2014-07-29 | 2017-08-22 | Therapeuticsmd Inc | creme transdérmico |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
ES2745819T3 (es) | 2014-08-07 | 2020-03-03 | Intra Cellular Therapies Inc | Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1 |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
CN107106563B (zh) | 2014-09-17 | 2021-05-25 | 细胞内治疗公司 | 化合物和方法 |
EP3226870B1 (en) | 2014-12-06 | 2019-09-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
BR112017012005B1 (pt) | 2014-12-06 | 2023-04-04 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NEW COMPOSITIONS AND METHODS |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
US11628171B2 (en) | 2019-03-13 | 2023-04-18 | Children's Medical Center Corporation | Method for treating brain or nerve injury |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
IL98559A0 (en) * | 1990-06-21 | 1992-07-15 | Schering Corp | Polycyclic guanine derivatives |
US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
CA2156918A1 (en) | 1993-02-26 | 1994-09-01 | Deen Tulshian | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6133273A (en) | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
YU23802A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
BR0014695A (pt) | 1999-10-11 | 2002-06-18 | Pfizer | 5-(2-substituìdo-5-heterociclilsulfonilpirid-3-il)-dihi dropirazolo[4,3-d]pirimidin-7-onas como inibidoras de fosfodiesterase |
IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
EP1278522B1 (en) | 2000-04-19 | 2006-10-25 | Lilly Icos LLC | Pde-v inhibitors for treatment of parkinson's disease |
MXPA03006310A (es) | 2001-03-16 | 2003-09-16 | Pfizer | Compuestos farmaceuticamente activos. |
WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
ES2302835T3 (es) | 2001-08-28 | 2008-08-01 | Schering Corporation | Inhibidores de fosfodiesterasa v policiclicos de guanina. |
ES2429132T3 (es) | 2001-08-31 | 2013-11-13 | The Rockefeller University | Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro |
WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
US20050153372A1 (en) | 2002-02-21 | 2005-07-14 | Paul Greengard | Compositions and method for regulation of calcium-dependent signaling in brain |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
WO2004087906A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
KR20050115331A (ko) | 2003-04-01 | 2005-12-07 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 불임증 포스포디에스터라제의 억제제 |
CN1878773A (zh) | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
CA2651519A1 (en) | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
US20070286890A1 (en) * | 2006-06-07 | 2007-12-13 | John Garnett Walt | Eyelash applicator and method |
ES2411604T3 (es) | 2006-11-13 | 2013-07-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
AU2008335811B2 (en) | 2007-12-06 | 2012-05-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2010006208A (es) | 2007-12-06 | 2010-12-21 | Intra Cellular Therapies Inc | Compuestos organicos. |
JP5710492B2 (ja) | 2008-12-06 | 2015-04-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
KR20110098732A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
BRPI0922808A2 (pt) | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
BRPI0922131A2 (pt) | 2008-12-06 | 2015-08-18 | Intracellular Therapies Inc | Compostos orgânicos |
US8536159B2 (en) * | 2008-12-06 | 2013-09-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP2012518685A (ja) | 2009-02-25 | 2012-08-16 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 眼障害のためのpde1阻害剤 |
JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
EP2485771A4 (en) | 2009-10-08 | 2014-11-12 | Intra Cellular Therapies Inc | PLATORS TARGETING PHOSPHODESTERASE 1 AND ASSOCIATED METHODS |
EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
WO2012171016A1 (en) * | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2009
- 2009-12-07 US US13/133,033 patent/US8536159B2/en active Active
- 2009-12-07 BR BRPI0922348-7A patent/BRPI0922348A2/pt not_active IP Right Cessation
- 2009-12-07 KR KR1020117013115A patent/KR20110095881A/ko not_active Application Discontinuation
- 2009-12-07 MX MX2011005933A patent/MX2011005933A/es not_active Application Discontinuation
- 2009-12-07 AU AU2009322901A patent/AU2009322901A1/en not_active Abandoned
- 2009-12-07 EA EA201170770A patent/EA201170770A1/ru unknown
- 2009-12-07 JP JP2011539520A patent/JP5778582B2/ja not_active Expired - Fee Related
- 2009-12-07 MA MA33969A patent/MA32938B1/fr unknown
- 2009-12-07 CA CA2740391A patent/CA2740391A1/en not_active Abandoned
- 2009-12-07 WO PCT/US2009/006439 patent/WO2010065149A1/en active Application Filing
- 2009-12-07 SG SG2011036589A patent/SG171775A1/en unknown
- 2009-12-07 ES ES09830744.0T patent/ES2638912T3/es active Active
- 2009-12-07 PE PE2011001169A patent/PE20110922A1/es not_active Application Discontinuation
- 2009-12-07 CN CN2009801480893A patent/CN102231953A/zh active Pending
- 2009-12-07 EP EP09830744.0A patent/EP2367429B1/en active Active
-
2011
- 2011-05-17 TN TN2011000246A patent/TN2011000246A1/fr unknown
- 2011-05-17 ZA ZA2011/03631A patent/ZA201103631B/en unknown
- 2011-05-30 CL CL2011001263A patent/CL2011001263A1/es unknown
- 2011-06-02 IL IL213314A patent/IL213314A0/en unknown
- 2011-06-06 CR CR20110312A patent/CR20110312A/es unknown
- 2011-06-06 DO DO2011000173A patent/DOP2011000173A/es unknown
- 2011-06-29 CO CO11081343A patent/CO6390083A2/es active IP Right Grant
- 2011-07-05 EC EC2011011184A patent/ECSP11011184A/es unknown
-
2013
- 2013-09-06 US US14/020,016 patent/US20140005155A1/en not_active Abandoned
-
2014
- 2014-10-03 US US14/506,394 patent/US20150038474A1/en not_active Abandoned
-
2015
- 2015-04-30 US US14/700,746 patent/US20160083390A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG171775A1 (en) | 2011-07-28 |
MX2011005933A (es) | 2011-12-16 |
US20110245214A1 (en) | 2011-10-06 |
CN102231953A (zh) | 2011-11-02 |
ECSP11011184A (es) | 2011-10-31 |
EP2367429B1 (en) | 2017-06-07 |
IL213314A0 (en) | 2011-07-31 |
BRPI0922348A2 (pt) | 2015-08-11 |
EP2367429A1 (en) | 2011-09-28 |
MA32938B1 (fr) | 2012-01-02 |
EP2367429A4 (en) | 2012-06-06 |
KR20110095881A (ko) | 2011-08-25 |
US20160083390A1 (en) | 2016-03-24 |
US8536159B2 (en) | 2013-09-17 |
US20140005155A1 (en) | 2014-01-02 |
EA201170770A1 (ru) | 2012-02-28 |
ZA201103631B (en) | 2013-05-29 |
CL2011001263A1 (es) | 2011-11-18 |
ES2638912T3 (es) | 2017-10-24 |
PE20110922A1 (es) | 2012-01-22 |
CA2740391A1 (en) | 2010-06-10 |
JP2012510993A (ja) | 2012-05-17 |
CO6390083A2 (es) | 2012-02-29 |
JP5778582B2 (ja) | 2015-09-16 |
WO2010065149A1 (en) | 2010-06-10 |
US20150038474A1 (en) | 2015-02-05 |
CR20110312A (es) | 2011-10-28 |
AU2009322901A1 (en) | 2010-06-10 |
TN2011000246A1 (en) | 2012-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000173A (es) | Compuestos organico | |
DOP2011000175A (es) | Compuestos organicos | |
ECSP12011910A (es) | Derivados de imidazopiridina como inhibidores de jak | |
ECSP11011183A (es) | Compuestos orgánicos | |
DOP2011000176A (es) | Compuestos organicos | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
DOP2011000171A (es) | Compuestos organico | |
UY30863A1 (es) | Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
HN2010001563A (es) | Compuestos | |
NI201000119A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
ECSP11011347A (es) | Nicotinamida sustituida como moduladores KCNQ2/3 | |
CO6640257A2 (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
ECSP11010830A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
SV2010003514A (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
CR20140031A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
ECSP11010992A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
CR20110703A (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt(pkb) | |
UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
NI201100015A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico. | |
UY32415A (es) | NUEVOS DERIVADOS DE TETRAHIDROPIRAZOLO[3,4-c]ISOQUINOLIN-5-AMINA | |
CR20130105A (es) | Derivados dihidrobenzoxatiazepinas, su preparación, composiciones farmacéuticas y utilización como moduladores de los receptores ampa | |
ECSP10010292A (es) | Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
UY29409A1 (es) | Compuestos de la ftalazina, aza- y diaza-ftalazina y metodos de uso |